IND application accepted for Aerie's AR-1105

The FDA has accepted an investigational new drug application for AR-1105, a treatment candidate for macular edema due to retinal vein occlusion, Aerie Pharmaceuticals announced in a press release.

AR-1105 (dexamethasone intravitreal implant) is a bioerodible implant designed to release the steroid over a 6-month period.

Aerie plans to begin a phase 2 clinical study later in the first quarter, the release said.

“This quarter we also plan to file an IND for our second retina product, a bioerodible implant containing the Rho kinase/protein kinase C inhibitor AR-13503 that is being developed for wet age-related macular degeneration and diabetic macular edema,” Aerie Chairman and CEO Vicente Anido Jr., PhD, said in the release.

The FDA has accepted an investigational new drug application for AR-1105, a treatment candidate for macular edema due to retinal vein occlusion, Aerie Pharmaceuticals announced in a press release.

AR-1105 (dexamethasone intravitreal implant) is a bioerodible implant designed to release the steroid over a 6-month period.

Aerie plans to begin a phase 2 clinical study later in the first quarter, the release said.

“This quarter we also plan to file an IND for our second retina product, a bioerodible implant containing the Rho kinase/protein kinase C inhibitor AR-13503 that is being developed for wet age-related macular degeneration and diabetic macular edema,” Aerie Chairman and CEO Vicente Anido Jr., PhD, said in the release.